These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36328579)

  • 1. Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI Study-observation).
    Takayama S; Yoshino T; Koizumi S; Irie Y; Suzuki T; Fujii S; Katori R; Kainuma M; Kobayashi S; Nogami T; Yokota K; Yamazaki M; Minakawa S; Chiba S; Suda N; Nakada Y; Ishige T; Maehara H; Tanaka Y; Nagase M; Kashio A; Komatsu K; Nojiri M; Shimooki O; Nakamoto K; Arita R; Ono R; Saito N; Kikuchi A; Ohsawa M; Nakae H; Mitsuma T; Mimura M; Ishii T; Nochioka K; Chiu SW; Yamaguchi T; Namiki T; Hisanaga A; Mitani K; Ito T
    Intern Med; 2023 Jan; 62(2):187-199. PubMed ID: 36328579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
    Namiki T; Takayama S; Arita R; Ishii T; Kainuma M; Makino T; Mimura M; Yoshino T; Nogami T; Arai M; Sato J; Tanaka K; Nakae H; Igari H; Ozawa Y; Shiko Y; Kawasaki Y; Nezu M; Ito T
    Trials; 2021 Jan; 22(1):23. PubMed ID: 33407828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial.
    Takayama S; Namiki T; Arita R; Ono R; Kikuchi A; Ohsawa M; Saito N; Suzuki S; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Takagi A; Yamaguchi T; Ishii T; Hisanaga A; Mitani K; Ito T
    J Infect Chemother; 2023 Nov; 29(11):1054-1060. PubMed ID: 37507087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and epidemiological features of healthcare workers after a coronavirus disease 2019 cluster infection in Japan and the effects of Kampo formulas-Hochuekkito and Kakkonto: A retrospective cohort study.
    Ogawa-Ochiai K; Ishikawa H; Nishimura H; Okajima M; Iinuma Y; Ito M
    Medicine (Baltimore); 2022 Jul; 101(28):e29748. PubMed ID: 35839019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients.
    Takayama S; Namiki T; Arita R; Ono R; Kikuchi A; Ohsawa M; Saito N; Suzuki S; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T; Hisanaga A; Mitani K; Ito T
    Front Pharmacol; 2022; 13():1008946. PubMed ID: 36438822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.
    Tokumasu K; Ueda K; Honda H; Sunada N; Sakurada Y; Matsuda Y; Nakano Y; Hasegawa T; Otsuka Y; Obika M; Hagiya H; Kataoka H; Otsuka F
    Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Ninjin'yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit.
    Aomatsu N; Shigemitsu K; Nakagawa H; Morooka T; Ishikawa J; Yamashita T; Tsuruoka A; Fuke A; Motoyama K; Kitagawa D; Ikeda K; Maeda K; Shirano M; Rinka H
    Neuropeptides; 2021 Dec; 90():102201. PubMed ID: 34753072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of COVID-19-Related Olfactory Disorder Promoted by Kakkontokasenkyushin'i: A Case Series.
    Takayama S; Arita R; Ono R; Saito N; Suzuki S; Kikuchi A; Ohsawa M; Tadano Y; Akaishi T; Tanaka J; Kanno T; Abe M; Onodera K; Ishii T
    Tohoku J Exp Med; 2021 Jun; 254(2):71-80. PubMed ID: 34108344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Japanese herbal Kampo medicines on live birth rate in women with recurrent pregnancy loss.
    Shigemi D; Hashimoto Y; Michihata N; Yasunaga H
    Int J Gynaecol Obstet; 2021 Jun; 153(3):489-495. PubMed ID: 33184912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid initiation timing and outcome of coronavirus disease 2019 patients: A multicenter, retrospective, observational study.
    Sugimoto R; Kenzaka T; Mikami A; Matsunaga N; Akiyama T; Ohmagari N; Nishisaki H
    Int J Immunopathol Pharmacol; 2023; 37():3946320231216314. PubMed ID: 37975809
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.
    Thomas S; Patel D; Bittel B; Wolski K; Wang Q; Kumar A; Il'Giovine ZJ; Mehra R; McWilliams C; Nissen SE; Desai MY
    JAMA Netw Open; 2021 Feb; 4(2):e210369. PubMed ID: 33576820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.